Skip to main content
Top
Published in: BMC Infectious Diseases 1/2020

01-12-2020 | Ritonavir | Research article

Prevalence and determinants of virological failure, genetic diversity and drug resistance among people living with HIV in a minority area in China: a population-based study

Authors: Dan Yuan, Meijing Liu, Peng Jia, Yiping Li, Yuling Huang, Li Ye, Laze Api, Maogang Chen, Liang Yao, Zixin Wang, Honglu Liu, Shu Liang, Shujuan Yang

Published in: BMC Infectious Diseases | Issue 1/2020

Login to get access

Abstract

Background

Liangshan Yi Autonomous Prefecture is one of the areas that most severely affected by human immunodeficiency virus (HIV) in China, and virological failure on antiretroviral therapy (ART) is serious in this area. Analyses of prevalence and determinants of ART failure, the genetic diversity and drug resistance among people living with HIV (PLWH) helps improve HIV treatment efficiency and prevent HIV transmission.

Methods

A total of 5157 PLWH were recruited from 2016 to 2017. The venous blood samples were subjected to RT-PCR, followed by sequencing of the HIV-1 pol gene, targeting the protease and reverse transcriptase fragments. HIV-1 diversity was analyzed using the DNAStar software and drug resistance mutations were analyzed using the Stanford University HIV Drug Resistance Database.

Results

A total of 2156 (41.81%) PLWH showed virological failure on ART. Males (ORm = 1.25), heterosexual behaviors and drug injection (ORm = 1.44) and mother to child transmission routes (ORm = 1.58), the clinical stage of AIDS (ORm = 1.35), having used illicit drugs and shared the needles (1–4 times: ORm = 1.34; more than 5 times: ORm = 1.52), having ever replaced ART regimen (ORm = 1.48) increased the risk of virological failure among PLWH, while higher education lever (ORm = 0.77) and ≥ 12 months on ART (12 ~ 36 months: ORm = 0.72; ≥36 months: ORm = 0.66) was associated with lower likelihood of virological failure. The data revealed that CRF07_BC (1508, 95.62%) were the most common strains, and the drug-resistant rate was 32.10% among PLWH with virological failure in this area. The high frequencies of drug resistance were found in EFV and NVP of NNRTIs, ABC, FTC and 3TC of NRTIs, and TPV/r in PIs. The most common mutations in NNRTIs, NRTIs and PIs were K103N/KN (64.69%), M184V/MV/I (36.29%) and Q58E/QE (4.93%), respectively.

Conclusion

We concluded that surveillance of virological failure, HIV-1 subtypes, and drug resistance to understand HIV-1 epidemiology and guide modification of ART guidelines, and target prevention and control strategies should be formatted to reduce the virological failure and drug resistance to promote viral suppression and prevent HIV-1 transmission.
Literature
2.
go back to reference Yang S, Luo M, Zhang S, Yao Y, Wang Q, Liao Q. Overview on culture and customs related to AIDS epidemic and prevention among Yi people in Liangshan. Chin J AIDS STD. 2017;23(3):101–5. Yang S, Luo M, Zhang S, Yao Y, Wang Q, Liao Q. Overview on culture and customs related to AIDS epidemic and prevention among Yi people in Liangshan. Chin J AIDS STD. 2017;23(3):101–5.
3.
go back to reference Zhao QG, Gong YH, Liao Q, Yu G, Wang K, Wang J, et al. Estimation on the HIV-1 incidence in Liangshan Yi autonomous prefecture, under BED-capture enzyme immunoassay, from 2011 to 2013. Zhonghua Liu Xing Bing Xue Za Zhi. 2016;37(8):1105–7.PubMed Zhao QG, Gong YH, Liao Q, Yu G, Wang K, Wang J, et al. Estimation on the HIV-1 incidence in Liangshan Yi autonomous prefecture, under BED-capture enzyme immunoassay, from 2011 to 2013. Zhonghua Liu Xing Bing Xue Za Zhi. 2016;37(8):1105–7.PubMed
4.
go back to reference Sun X, Lu F, Wu Z, Poundstone K, Zeng G, Xu P, et al. Evolution of information-driven HIV/AIDS policies in China. Int J Epidemiol. 2010;1(Suppl 2):ii4–13. Sun X, Lu F, Wu Z, Poundstone K, Zeng G, Xu P, et al. Evolution of information-driven HIV/AIDS policies in China. Int J Epidemiol. 2010;1(Suppl 2):ii4–13.
5.
go back to reference Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the international antiviral society-USA panel. JAMA. 2014;312(4):410–25.PubMed Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the international antiviral society-USA panel. JAMA. 2014;312(4):410–25.PubMed
6.
go back to reference Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedPubMedCentral Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedPubMedCentral
7.
go back to reference Beyrer C, Pozniak A. HIV drug resistance - an emerging threat to epidemic control. N Engl J Med. 2017;377(17):1605–7.PubMed Beyrer C, Pozniak A. HIV drug resistance - an emerging threat to epidemic control. N Engl J Med. 2017;377(17):1605–7.PubMed
8.
go back to reference Zhu H, Napravnik S, Eron JJ, Cole SR, Ma Y, Wohl DA, et al. Decreasing excess mortality of HIV-infected patients initiating antiretroviral therapy: comparison with mortality in general population in China, 2003-2009. J Acquir Immune Defic Syndr. 2013;63(5):e150–7.PubMedPubMedCentral Zhu H, Napravnik S, Eron JJ, Cole SR, Ma Y, Wohl DA, et al. Decreasing excess mortality of HIV-infected patients initiating antiretroviral therapy: comparison with mortality in general population in China, 2003-2009. J Acquir Immune Defic Syndr. 2013;63(5):e150–7.PubMedPubMedCentral
9.
go back to reference Sanguansittianant S, Nooroon N, Phaengchomduan P, Ammaranond P. Trends in prevalence of HIV-1 drug resistance in Thailand 2009-2010. J Clin Lab Anal. 2013;27(5):346–53.PubMedPubMedCentral Sanguansittianant S, Nooroon N, Phaengchomduan P, Ammaranond P. Trends in prevalence of HIV-1 drug resistance in Thailand 2009-2010. J Clin Lab Anal. 2013;27(5):346–53.PubMedPubMedCentral
10.
go back to reference Yang CB, Yang W, Zeng YL, Gu XD, Bian SC, Wu M, et al. Effect of early antiretroviral therapy on acquired immune deficiency syndrome in Butuo County, Liangshan autonomous prefecture. West China Med J. 2017;32(6):867–70. Yang CB, Yang W, Zeng YL, Gu XD, Bian SC, Wu M, et al. Effect of early antiretroviral therapy on acquired immune deficiency syndrome in Butuo County, Liangshan autonomous prefecture. West China Med J. 2017;32(6):867–70.
11.
go back to reference Xu JL, Jike KCN, Ma Y, Yu G, Wang J, Wang K, et al. Effects and associated factors of HIV/AIDS anti-retroviral therapy in Liangshan Yi autonomous refecture, Sichuan Province. Zhonghua Yu Fang Yi Xue Za Zhi. 2018;52(6):668–72.PubMed Xu JL, Jike KCN, Ma Y, Yu G, Wang J, Wang K, et al. Effects and associated factors of HIV/AIDS anti-retroviral therapy in Liangshan Yi autonomous refecture, Sichuan Province. Zhonghua Yu Fang Yi Xue Za Zhi. 2018;52(6):668–72.PubMed
12.
go back to reference Dou Z, Zhang F, Zhao Y, Jin C, Zhao D, Gan X, et al. Progress on China s national free antiretroviral therapy strategy in 2002-2014. Zhonghua Liu Xing Bing Xue Za Zhi. 2015;36(12):1345–50.PubMed Dou Z, Zhang F, Zhao Y, Jin C, Zhao D, Gan X, et al. Progress on China s national free antiretroviral therapy strategy in 2002-2014. Zhonghua Liu Xing Bing Xue Za Zhi. 2015;36(12):1345–50.PubMed
13.
go back to reference Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292–307.PubMedPubMedCentral Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292–307.PubMedPubMedCentral
14.
go back to reference Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips A, et al. Resistance. UCGoHD: persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 2013;208(9):1459–63.PubMedPubMedCentral Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips A, et al. Resistance. UCGoHD: persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 2013;208(9):1459–63.PubMedPubMedCentral
15.
go back to reference Leigh Brown AJ, Lycett SJ, Weinert L, Hughes GJ, Fearnhill E, Dunn DT. Collaboration. UHDR: transmission network parameters estimated from HIV sequences for a nationwide epidemic. J Infect Dis. 2011;204(9):1463–9.PubMedPubMedCentral Leigh Brown AJ, Lycett SJ, Weinert L, Hughes GJ, Fearnhill E, Dunn DT. Collaboration. UHDR: transmission network parameters estimated from HIV sequences for a nationwide epidemic. J Infect Dis. 2011;204(9):1463–9.PubMedPubMedCentral
16.
go back to reference Hemelaar J. Implications of HIV diversity for the HIV-1 pandemic. J Inf Secur. 2013;66(5):391–400. Hemelaar J. Implications of HIV diversity for the HIV-1 pandemic. J Inf Secur. 2013;66(5):391–400.
17.
go back to reference Song YX, Xin RL, Li ZC, Yu HW, Lun WH, Ye J, et al. Prevalence of transmitted drug resistance among HIV-1 treatment-naive patients in Beijing. Epidemiol Infect. 2018;146(3):339–44.PubMed Song YX, Xin RL, Li ZC, Yu HW, Lun WH, Ye J, et al. Prevalence of transmitted drug resistance among HIV-1 treatment-naive patients in Beijing. Epidemiol Infect. 2018;146(3):339–44.PubMed
18.
go back to reference Xiao P, Zhou Y, Lu J, Yan L, Xu X, Hu H, et al. HIV-1 genotype diversity and distribution characteristics among heterosexually transmitted population in Jiangsu province, China. Virol J. 2019;16(1):51.PubMedPubMedCentral Xiao P, Zhou Y, Lu J, Yan L, Xu X, Hu H, et al. HIV-1 genotype diversity and distribution characteristics among heterosexually transmitted population in Jiangsu province, China. Virol J. 2019;16(1):51.PubMedPubMedCentral
19.
go back to reference Li X, Li W, Zhong P, Fang K, Zhu K, Musa TH, et al. Nationwide trends in molecular epidemiology of HIV-1 in China. AIDS Res Hum Retrovir. 2016;32(9):851–9.PubMed Li X, Li W, Zhong P, Fang K, Zhu K, Musa TH, et al. Nationwide trends in molecular epidemiology of HIV-1 in China. AIDS Res Hum Retrovir. 2016;32(9):851–9.PubMed
20.
go back to reference Borghetti A, Moschese D, Cingolani A, Baldin G, Speziale D, Ciccullo A, et al. Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure. HIV Med. 2019;20(9):624–7.PubMed Borghetti A, Moschese D, Cingolani A, Baldin G, Speziale D, Ciccullo A, et al. Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure. HIV Med. 2019;20(9):624–7.PubMed
21.
go back to reference Amstutz A, Nsakala BL, Vanobberghen F, Muhairwe J, Glass TR, Achieng B, et al. SESOTHO trial (“switch either near suppression or THOusand”) - switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL: protocol of a multicenter, parallel-group, open-label, randomized clinical trial in Lesotho, southern Africa. BMC Infect Dis. 2018;18(1):76.PubMedPubMedCentral Amstutz A, Nsakala BL, Vanobberghen F, Muhairwe J, Glass TR, Achieng B, et al. SESOTHO trial (“switch either near suppression or THOusand”) - switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL: protocol of a multicenter, parallel-group, open-label, randomized clinical trial in Lesotho, southern Africa. BMC Infect Dis. 2018;18(1):76.PubMedPubMedCentral
22.
go back to reference Yuan D, Su L, Liu H, Yu H, Yang H, Ye L, et al. Drug-resistance characteristics of CRF01_AE and CRF07_BC subtypes of HIV-1 strains in Sichuan province. Zhonghua Yu Fang Yi Xue Za Zhi. 2015;49(10):901–6.PubMed Yuan D, Su L, Liu H, Yu H, Yang H, Ye L, et al. Drug-resistance characteristics of CRF01_AE and CRF07_BC subtypes of HIV-1 strains in Sichuan province. Zhonghua Yu Fang Yi Xue Za Zhi. 2015;49(10):901–6.PubMed
23.
go back to reference Yuan D, Du Z, Zhou J, Ye L, Su L, Yang H, et al. HIV-1 subtype diversity, drug resistance, and genetic transmission networks in men who have sex with men with virologic failure in antiretroviral therapy in Sichuan, China, 2011 to 2017. Medicine (Baltimore). 2019;98(43):e17585. Yuan D, Du Z, Zhou J, Ye L, Su L, Yang H, et al. HIV-1 subtype diversity, drug resistance, and genetic transmission networks in men who have sex with men with virologic failure in antiretroviral therapy in Sichuan, China, 2011 to 2017. Medicine (Baltimore). 2019;98(43):e17585.
24.
go back to reference Xiaoli C, Yun L, Junbin L, Fengyu H, Weiping C. Analysis on drug resistance in HIV/AIDS patients with HAART through different infection routes in Guangdong. Chin J AIDS STD. 2015;21(5):369–72. Xiaoli C, Yun L, Junbin L, Fengyu H, Weiping C. Analysis on drug resistance in HIV/AIDS patients with HAART through different infection routes in Guangdong. Chin J AIDS STD. 2015;21(5):369–72.
25.
go back to reference Maojiao L. Analysis of genotype resistance variation and subtypes of HIV-1 in Honghe prefecture, Yunnan. Dali: Dali University; 2018. Maojiao L. Analysis of genotype resistance variation and subtypes of HIV-1 in Honghe prefecture, Yunnan. Dali: Dali University; 2018.
26.
go back to reference Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. Factors associated with Virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, august 2014-July 2015. BMC Infect Dis. 2017;17(1):326.PubMedPubMedCentral Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. Factors associated with Virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, august 2014-July 2015. BMC Infect Dis. 2017;17(1):326.PubMedPubMedCentral
27.
go back to reference Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One. 2013;8(2):e55824.PubMedPubMedCentral Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One. 2013;8(2):e55824.PubMedPubMedCentral
28.
go back to reference Tran DA, Wilson DP, Shakeshaft A, Ngo AD, Doran C, Zhang L. Determinants of virological failure after 1 year's antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces. Sex Transm Infect. 2014;90(7):538–44.PubMed Tran DA, Wilson DP, Shakeshaft A, Ngo AD, Doran C, Zhang L. Determinants of virological failure after 1 year's antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces. Sex Transm Infect. 2014;90(7):538–44.PubMed
29.
go back to reference Jordan MR, Obeng-Aduasare Y, Sheehan H, Hong SY, Terrin N, Duong DV, et al. Correlates of non-adherence to antiretroviral therapy in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, Vietnam. Int J STD AIDS. 2014;25(9):662–8.PubMed Jordan MR, Obeng-Aduasare Y, Sheehan H, Hong SY, Terrin N, Duong DV, et al. Correlates of non-adherence to antiretroviral therapy in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, Vietnam. Int J STD AIDS. 2014;25(9):662–8.PubMed
30.
go back to reference Cauldbeck MB, O'Connor C, O'Connor MB, Saunders JA, Rao B, Mallesh VG, et al. Adherence to anti-retroviral therapy among HIV patients in Bangalore, India. AIDS Res Ther. 2009;6:7.PubMedPubMedCentral Cauldbeck MB, O'Connor C, O'Connor MB, Saunders JA, Rao B, Mallesh VG, et al. Adherence to anti-retroviral therapy among HIV patients in Bangalore, India. AIDS Res Ther. 2009;6:7.PubMedPubMedCentral
31.
go back to reference Chawana TD, Reid A, Bwakura T, Gavi S, Nhachi CF. Factors influencing treatment failure in HIV positive adult patients on first line antiretroviral therapy. Cent Afr J Med. 2014;60(5–8):29–36.PubMed Chawana TD, Reid A, Bwakura T, Gavi S, Nhachi CF. Factors influencing treatment failure in HIV positive adult patients on first line antiretroviral therapy. Cent Afr J Med. 2014;60(5–8):29–36.PubMed
32.
go back to reference Jean Louis F, Buteau J, Francois K, Hulland E, Domercant JW, Yang C, et al. Virologic outcome among patients receiving antiretroviral therapy at five hospitals in Haiti. PLoS One. 2018;13(1):e0192077.PubMedPubMedCentral Jean Louis F, Buteau J, Francois K, Hulland E, Domercant JW, Yang C, et al. Virologic outcome among patients receiving antiretroviral therapy at five hospitals in Haiti. PLoS One. 2018;13(1):e0192077.PubMedPubMedCentral
33.
go back to reference Kyaw NT, Harries AD, Kumar AM, Oo MM, Kyaw KW, Win T, et al. High rate of virological failure and low rate of switching to second-line treatment among adolescents and adults living with HIV on first-line ART in Myanmar, 2005-2015. PLoS One. 2017;12(2):e0171780.PubMedPubMedCentral Kyaw NT, Harries AD, Kumar AM, Oo MM, Kyaw KW, Win T, et al. High rate of virological failure and low rate of switching to second-line treatment among adolescents and adults living with HIV on first-line ART in Myanmar, 2005-2015. PLoS One. 2017;12(2):e0171780.PubMedPubMedCentral
34.
go back to reference Yu X-F, Chen J, Shao Y, Beyrer C, Lai S. Two subtypes of HIV-1 among injection-drug users in southern China. Lancet. 1998;351:9111. Yu X-F, Chen J, Shao Y, Beyrer C, Lai S. Two subtypes of HIV-1 among injection-drug users in southern China. Lancet. 1998;351:9111.
35.
go back to reference Yu ES, Xie Q, Zhang K, Lu P, Chan LL. HIV infection and AIDS in China, 1985 through 1994. Am J Public Health. 1996;86(8):1116–22.PubMedPubMedCentral Yu ES, Xie Q, Zhang K, Lu P, Chan LL. HIV infection and AIDS in China, 1985 through 1994. Am J Public Health. 1996;86(8):1116–22.PubMedPubMedCentral
36.
go back to reference Lin YT, Lan YC, Chen YJ, Huang YH, Lee CM, Liu TT, et al. Molecular epidemiology of HIV-1 infection and full-length genomic analysis of circulating recombinant form 07_BC strains from injection drug users in Taiwan. J Infect Dis. 2007;195(9):1283–93.PubMed Lin YT, Lan YC, Chen YJ, Huang YH, Lee CM, Liu TT, et al. Molecular epidemiology of HIV-1 infection and full-length genomic analysis of circulating recombinant form 07_BC strains from injection drug users in Taiwan. J Infect Dis. 2007;195(9):1283–93.PubMed
37.
go back to reference He X, Xing H, Ruan Y, Hong K, Cheng C, Hu Y, et al. A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey. PLoS One. 2012;7(10):e47289.PubMedPubMedCentral He X, Xing H, Ruan Y, Hong K, Cheng C, Hu Y, et al. A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey. PLoS One. 2012;7(10):e47289.PubMedPubMedCentral
38.
go back to reference Su L, Graf M, Zhang Y, von Briesen H, Xing H, Köstler J, et al. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B’) recombinant strain in China. J Virol. 2000;74(23):11367–76.PubMedPubMedCentral Su L, Graf M, Zhang Y, von Briesen H, Xing H, Köstler J, et al. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B’) recombinant strain in China. J Virol. 2000;74(23):11367–76.PubMedPubMedCentral
39.
go back to reference Piyasirisilp S, McCutchan FE, Carr JK, Sanders-Buell E, Liu W, Chen J, et al. A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. J Virol. 2000;74(23):11286–95.PubMedPubMedCentral Piyasirisilp S, McCutchan FE, Carr JK, Sanders-Buell E, Liu W, Chen J, et al. A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. J Virol. 2000;74(23):11286–95.PubMedPubMedCentral
40.
go back to reference Tee KK, Pybus OG, Li XJ, Han X, Shang H, Kamarulzaman A, et al. Temporal and spatial dynamics of human immunodeficiency virus type 1 circulating recombinant forms 08_BC and 07_BC in Asia. J Virol. 2008;82(18):9206–15.PubMedPubMedCentral Tee KK, Pybus OG, Li XJ, Han X, Shang H, Kamarulzaman A, et al. Temporal and spatial dynamics of human immunodeficiency virus type 1 circulating recombinant forms 08_BC and 07_BC in Asia. J Virol. 2008;82(18):9206–15.PubMedPubMedCentral
41.
go back to reference Zhefeng M, Jingyun L, Ping Z, Jianqing X, Xiaoyan Z. A new transmission map of HIV-1 CRF07_BC in China: analysis of sequences from 12 provinces over a decade. Retrovirology. 2012;9(S2):P139.PubMedCentral Zhefeng M, Jingyun L, Ping Z, Jianqing X, Xiaoyan Z. A new transmission map of HIV-1 CRF07_BC in China: analysis of sequences from 12 provinces over a decade. Retrovirology. 2012;9(S2):P139.PubMedCentral
42.
go back to reference Qixing W, Suhua Z, Shujuan Y, Qiang L, Gang Y, Yongnan Y, et al. Characteristics of transmission route among the reported HIV infections during 2011-2014 in Liangshan prefecture. Chin J AIDS STD. 2017;23(8):719–22. Qixing W, Suhua Z, Shujuan Y, Qiang L, Gang Y, Yongnan Y, et al. Characteristics of transmission route among the reported HIV infections during 2011-2014 in Liangshan prefecture. Chin J AIDS STD. 2017;23(8):719–22.
43.
go back to reference Hou LJ, Wang HW, Duan SP, Zhuo Y, Zhou YC, Wu HJ, et al. The prevalence and determinants of drug-resistance-associated mutations in the HIV-1-infected MSM population of Henan Province in China. Arch Virol. 2015;160(8):2051–61.PubMed Hou LJ, Wang HW, Duan SP, Zhuo Y, Zhou YC, Wu HJ, et al. The prevalence and determinants of drug-resistance-associated mutations in the HIV-1-infected MSM population of Henan Province in China. Arch Virol. 2015;160(8):2051–61.PubMed
44.
45.
go back to reference Menéndez-Arias L. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol Sci. 2002;23(8):381–8.PubMed Menéndez-Arias L. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol Sci. 2002;23(8):381–8.PubMed
46.
go back to reference Cunningham E, Chan YT, Aghaizu A, Bibby DF, Murphy G, Tosswill J, et al. Enhanced surveillance of HIV-1 drug resistance in recently infected MSM in the UK. J Antimicrob Chemother. 2017;72(1):227–34.PubMed Cunningham E, Chan YT, Aghaizu A, Bibby DF, Murphy G, Tosswill J, et al. Enhanced surveillance of HIV-1 drug resistance in recently infected MSM in the UK. J Antimicrob Chemother. 2017;72(1):227–34.PubMed
47.
go back to reference WHO. HIV drug resistance report 2017. Geneva: World Health Organization; 2017. WHO. HIV drug resistance report 2017. Geneva: World Health Organization; 2017.
48.
go back to reference Nsanzimana S, Semakula M, Ndahindwa V, Remera E, Sebuhoro D, Uwizihiwe JP, et al. Retention in care and virological failure among adult HIV+ patients on second-line ART in Rwanda: a national representative study. BMC Infect Dis. 2019;19(1):312.PubMedPubMedCentral Nsanzimana S, Semakula M, Ndahindwa V, Remera E, Sebuhoro D, Uwizihiwe JP, et al. Retention in care and virological failure among adult HIV+ patients on second-line ART in Rwanda: a national representative study. BMC Infect Dis. 2019;19(1):312.PubMedPubMedCentral
Metadata
Title
Prevalence and determinants of virological failure, genetic diversity and drug resistance among people living with HIV in a minority area in China: a population-based study
Authors
Dan Yuan
Meijing Liu
Peng Jia
Yiping Li
Yuling Huang
Li Ye
Laze Api
Maogang Chen
Liang Yao
Zixin Wang
Honglu Liu
Shu Liang
Shujuan Yang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2020
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-020-05124-1

Other articles of this Issue 1/2020

BMC Infectious Diseases 1/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.